Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00500110 · ClinicalTrials.gov registry record · Phase 2
Hormonal Ablation, Imatinib Mesylate and Docetaxel for Patients With Prostate Cancer
A Phase 2 study, sponsored by M.D. Anderson Cancer Center.
- Completed
- Registry status
- Phase 2
- Development phase
- 39
- Enrollment target
NCT00500110: Completed Phase 2 study, sponsored by M.D. Anderson Cancer Center.
NCT00500110 is a Phase 2 study that has completed, run by M.D. Anderson Cancer Center. The registered enrollment target is 39 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00500110, a Phase 2 study, has completed, sponsored by M.D. Anderson Cancer Center.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 39 participants
- Enrollment target
Study Summary
Primary Objective: 1\. To evaluate the pathological complete response rate to neoadjuvant hormonal ablation, Imatinib and Docetaxel (HID) in high-risk localized prostate cancer. Secondary Objectives: 1. To describe the time to prostate specific antigen (PSA)-progression after neoadjuvant HID and radical prostatectomy in high-risk localized prostate cancer. 2. To correlate pathological response with modulation of the Platelet-Derived Growth Factor Receptor (PDGFR) pathway.
Interventions
- DRUG Docetaxel
- DRUG Goserelin Acetate
- DRUG Leuprolide
- DRUG Imatinib Mesylate
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 39 participants |
| Start Date | 2003-06 |
| Est. Completion | 2010-02 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00500110
The ClinicalTrials.gov registry entry for NCT00500110 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 39 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is M.D. Anderson Cancer Center, which has 2,692 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which Docetaxel is the first listed.
NCT00500110 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00500110 about?
NCT00500110 is a clinical study titled "Hormonal Ablation, Imatinib Mesylate and Docetaxel for Patients With Prostate Cancer". Primary Objective: 1\. To evaluate the pathological complete response rate to neoadjuvant hormonal ablation, Imatinib and Docetaxel (HID) in high-risk localized prostate cancer. Secondary Objectives: 1. To describe the time to prostate specific antigen (PSA)-progression after neoadjuvant HID and ...
What is the current status of trial NCT00500110?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 39 participants. The study started on 2003-06. Estimated completion is 2010-02.
What interventions are being tested in trial NCT00500110?
The interventions under investigation include: Docetaxel (DRUG), Goserelin Acetate (DRUG), Leuprolide (DRUG), Imatinib Mesylate (DRUG).
Who is sponsoring clinical trial NCT00500110?
This trial is sponsored by M.D. Anderson Cancer Center, which has 2,692 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.